ClinicalTrials.gov 临床试验·· 6 天前AI 评分38
RadiCaL II期试验:镭-223二氯化物联合卡博替尼治疗骨转移性晚期肾细胞癌
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
AI 导读
一项II期试验正在评估在常规治疗卡博替尼基础上加用镭-223二氯化物,能否改善骨转移性肾细胞癌患者的结局。镭-223二氯化物可将辐射直接靶向癌细胞并减少对正常细胞的损伤,卡博替尼则通过阻断癌细胞生长所需的某些酶抑制肿瘤生长。联合用药可能较单用卡博替尼减轻骨转移性肾细胞癌患者的疼痛和症状。
来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov